Pediatric Hematology/Oncology and Immunopathology

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

1726-17082414-9314

Fund Doctors, Innovations, Science for Children

618

10.24287/1726-1708-2022-21-2-66-77

ORIGINAL ARTICLES

ОРИГИНАЛЬНЫЕ СТАТЬИ

Nasopharyngeal carcinoma in children and adolescents: a literature review and our own data

Назофарингеальная карцинома у детей и подростков. Обзор литературы и собственные данные

https://orcid.org/0000-0002-9054-5068

Zhukov

N. V.

Жуков

Н. В.

Russian Federation

Nikolay V. Zhukov, Dr. Med. Sci, Professor, Head of the Department of Interdisciplinary Oncology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation, Assistant Professor at the Department of Oncology, Hematology and Radiotherapy, N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian Federation

1 Samory Mashela St., Moscow 117997

Жуков Николай Владимирович, д-р мед. наук, профессор, заведующий отделом междисциплинарной онкологии ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России, доцент кафедры онкологии, гематологии и лучевой терапии ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России

117997, Москва, ул. Саморы Машела, 1

zhukov.nikolay@rambler.ru

https://orcid.org/0000-0001-9450-125X

Rabaeva

L. L.

Рабаева

Л. Л.

Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России

N.I. Pirogov Russian National Research Medical University of Ministry of Healthcare of the Russian FederationФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России

08072022

212

66772406202224062022

2025

«D. Rogachev NMRCPHOI»

ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России

https://creativecommons.org/licenses/by/4.0

https://hemoncim.com/jour/article/view/618

Nasopharyngeal carcinoma (NPC) is one of the few epithelial tumors that regularly occur in the pediatric population. The majority of patients with localized and locally advanced NPC can be cured with current treatment protocols which include platinum-based induction therapy followed by chemoradiation therapy. The prognosis of patients with initially metastatic NPC and recurrent disease after prior curative treatment is, however, still unfavorable. Fortunately, new treatment options such as immune checkpoints inhibitors and supportive treatment with oral fluoropyrimidine give hope for better outcomes in these patients as well. It's important to note that the management of NPC diagnosed in adults and children allows for the adaptation of effective treatment approaches for either of the age groups. An analysis of our own data suggests that current treatment protocols for NPC can be successfully adopted by Russian clinics and can help to achieve treatment outcomes comparable to the results obtained in other countries.

The purpose of this article is to overview current therapeutic approaches for NPC and possible ways of their improvement based on our own and literature data. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology.

Назофарингеальная карцинома (НФК) – одна из немногих эпителиальных опухолей, регулярно встречающихся в детской и подростковой популяции. Современные протоколы лечения, предусматривающие проведение платиносодержащей индукционной химиотерапии с последующей химиолучевой терапией, позволяют излечить большинство пациентов с локализованными и местно-распространенными стадиями болезни. Однако прогноз больных с первично-метастатической формой НФК и рецидивами заболевания после ранее проведенного куративного лечения и в настоящее время остается неблагоприятным. Появление новых лечебных опций (ингибиторы контрольных точек иммунитета, поддерживающая терапия пероральными фторпиримидинами) позволяет надеяться на улучшение результатов и у этих категорий больных. Важной особенностью НФК, встречающейся как у детей, так и у взрослых, является возможность взаимной адаптации успешных подходов для каждой из возрастных групп. Как показывает анализ собственных данных, современные протоколы лечения НФК могут быть успешно адаптированы в клиниках Российской Федерации, а их использование позволяет добиться результатов, сопоставимых с зарубежными. Целью этой статьи является ознакомление с современными подходами терапии НФК, возможными путями их совершенствования на основании собственных и литературных данных. Настоящее исследование одобрено независимым этическим комитетом и утверждено решением ученого совета НМИЦ ДГОИ им. Дмитрия Рогачева.

SARS-CoV-2coronavirus infectionCOVID-19virus-specific T lymphocyteshematopoietic stem cell transplantationallogeneic hematopoietic stem cell transplantationpneumoniaprimary immunodeficiency

назофарингеальная карциноманосоглоткаэпителиальная опухольдетиметастатическая формарецидив

Not specified

Не указан

1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424. DOI: 10.3322/caac.21492

Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality world-wide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (6): 394–424. DOI: 10.3322/caac.21492

2. Thompson L. D. Update on nasopharyngeal carcinoma. Head Neck Pathol 2007; 1 (1): 81–6. DOI: 10.1007/s12105-007-0012-7

Thompson L. D. Update on nasopharyngeal carcinoma. Head Neck Pathol 2007; 1 (1): 81–6. DOI: 10.1007/s12105-007-0012-7

3. Henle G., Henle W. Epstein–Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17: 1–7.

Henle G., Henle W. Epstein–Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976; 17: 1–7.

4. Ayan I., Kaytan E., Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol 2003; 4(1): 13–21.

Ayan I., Kaytan E., Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol 2003; 4(1): 13–21.

5. Sultan I., Casanova M., Ferrari A., Rihani R., Rodriguez-Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer 2010; 55 (2): 279–84.

Sultan I., Casanova M., Ferrari A., Rihani R., Rodriguez-Galindo C. Differential features of nasopharyngeal carcinoma in children and adults: a SEER study. Pediatr Blood Cancer 2010; 55 (2): 279–84.

6. Richards M. K., Dahl J. P., Gow K., Goldin A. B., Doski J., Goldfarb М., et al. Factors Associated With Mortality in Pediatric vs Adult Nasopharyngeal Carcinoma. JAMA Otolaryngol Head Neck Surg 2016; 142 (3): 217–22.

Richards M. K., Dahl J. P., Gow K., Goldin A. B., Doski J., Goldfarb М., et al. Factors Associated With Mortality in Pediatric vs Adult Nasopharyngeal Carcinoma. JAMA Otolaryngol Head Neck Surg 2016; 142 (3): 217–22.

7. Dawson C. W., Port R. J., Young L. S. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 2012; 22 (2): 144–53.

Dawson C. W., Port R. J., Young L. S. The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Semin Cancer Biol 2012; 22 (2): 144–53.

8. Lo Y. M., Chan L. Y., Lo K. W., Leung S. F., Zhang J., Chan A. T., et al. Quantitative analysis of cell-free Epstein–Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59 (6): 1188–91.

Lo Y. M., Chan L. Y., Lo K. W., Leung S. F., Zhang J., Chan A. T., et al. Quantitative analysis of cell-free Epstein–Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999; 59 (6): 1188–91.

9. Afquir S., Ismaili N., Alaoui K., Ahid S., Lotz J. P., Horn Е., et al. Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients. Eur Arch Otorhinolaryngol 2009; 266: 1767–73.

Afquir S., Ismaili N., Alaoui K., Ahid S., Lotz J. P., Horn Е., et al. Nasopharyngeal carcinoma in adolescents: a retrospective review of 42 patients. Eur Arch Otorhinolaryngol 2009; 266: 1767–73.

10.

10. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность) / Под ред.: Каприна А. Д., Старинского В. В., Петровой Г. В. – М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.

Злокачественные новообразования в России в 2018 году (заболеваемость и смертность) / Под ред.: Каприна А. Д., Старинского В. В., Петровой Г. В. – М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019.

11.

11. Greene M. H., Fraumeni J. F, Hoover R. Nasopharyngeal cancer among young people in the United States: Racial variations by cell type. J Natl Cancer Inst 1977; 58: 1267–70.

Greene M. H., Fraumeni J. F, Hoover R. Nasopharyngeal cancer among young people in the United States: Racial variations by cell type. J Natl Cancer Inst 1977; 58: 1267–70.

12.

12. Richards M. K., Dahl J. P., Gow K., Goldin A. B., Doski J., Goldfarb M., et al. Factors Associated With Mortality in Pediatric vs Adult Nasopharyngeal Carcinoma. JAMA Otolaryngol Head Neck Surg 2016; 142 (3): 217–22.

Richards M. K., Dahl J. P., Gow K., Goldin A. B., Doski J., Goldfarb M., et al. Factors Associated With Mortality in Pediatric vs Adult Nasopharyngeal Carcinoma. JAMA Otolaryngol Head Neck Surg 2016; 142 (3): 217–22.

13.

13. Brennan B. Nasopharyngeal carcinoma [serial online]. Orphanet J Rare Dis 2006; 1: 23.

Brennan B. Nasopharyngeal carcinoma [serial online]. Orphanet J Rare Dis 2006; 1: 23.

14.

14. Ayan I., Altun M. Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol-Phys 1996; 35: 485–92.

Ayan I., Altun M. Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol-Phys 1996; 35: 485–92.

15.

15. Lee A. W. M., Lydiatt W. M., Colevas A. D., et al.: Nasopharynx. In: Amin M. B., Edge S. B., Greene F. L., et al., eds.: AJCC Cancer Staging Manual. 8 th ed. New York, NY: Springer; 2017. Рp. 103–111.

Lee A. W. M., Lydiatt W. M., Colevas A. D., et al.: Nasopharynx. In: Amin M. B., Edge S. B., Greene F. L., et al., eds.: AJCC Cancer Staging Manual. 8 th ed. New York, NY: Springer; 2017. Рp. 103–111.

16.

16. Khor T. H., Tan B. C., Chua E. J., Chia K. B. Distant metastases in nasopharyngeal carcinoma. Clin Radiol 1978; 29 (1): 27–30.

Khor T. H., Tan B. C., Chua E. J., Chia K. B. Distant metastases in nasopharyngeal carcinoma. Clin Radiol 1978; 29 (1): 27–30.

17.

17. Buehrlen M., Zwaan C. M., Granzen B., Lassay L., Deutz P., Vorwerk P., et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer 2012; 118 (19): 4892–900.

Buehrlen M., Zwaan C. M., Granzen B., Lassay L., Deutz P., Vorwerk P., et al. Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG. Cancer 2012; 118 (19): 4892–900.

18.

18. Casanova M., Bisogno G., Gandola L., Cecchetto G., Di Cataldo A., Basso Е., et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer 2012; 118 (10): 2718–25.

Casanova M., Bisogno G., Gandola L., Cecchetto G., Di Cataldo A., Basso Е., et al. A prospective protocol for nasopharyngeal carcinoma in children and adolescents: the Italian Rare Tumors in Pediatric Age (TREP) project. Cancer 2012; 118 (10): 2718–25.

19.

19. Cheuk D. K., Billups C. A., Martin M. G., Roland C. R., Ribeiro R. C., Krasin M. J., Rodriguez-Galindo C. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 2011; 117 (1): 197–206.

Cheuk D. K., Billups C. A., Martin M. G., Roland C. R., Ribeiro R. C., Krasin M. J., Rodriguez-Galindo C. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 2011; 117 (1): 197–206.

20.

20. Lee A. W., Ng W. T., Pan J. J., Chiang C. L., Poh S. S., Choi H. C., et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2019; 105 (3): 567–80. DOI: 10.1016/j.ijrobp.2019.06.254

Lee A. W., Ng W. T., Pan J. J., Chiang C. L., Poh S. S., Choi H. C., et al. International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys 2019; 105 (3): 567–80. DOI: 10.1016/j.ijrobp.2019.06.254

21.

21. Du T., Xiao J., Qiu Z., Wu K. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. PLoS One 2019; 14: e0219611.

Du T., Xiao J., Qiu Z., Wu K. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis. PLoS One 2019; 14: e0219611.

22.

22. You R., Cao Y. S., Huang P. Y., Chen L., Yang Q., Liu Y. P., et al. The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two / threedimensional radiotherapy to intensity-modulated radiotherapy: A network meta-analysis. Theranostics 2017; 7: 4825–35.

You R., Cao Y. S., Huang P. Y., Chen L., Yang Q., Liu Y. P., et al. The changing therapeutic role of chemo-radiotherapy for loco-regionally advanced nasopharyngeal carcinoma from two / threedimensional radiotherapy to intensity-modulated radiotherapy: A network meta-analysis. Theranostics 2017; 7: 4825–35.

23.

23. Ribassin-Majed L., Marguet S., Lee A. W. M., Ng W. T., Ma J., Chan A. T. С., et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. J Clin Oncol 2017; 35 (5): 498–505.

Ribassin-Majed L., Marguet S., Lee A. W. M., Ng W. T., Ma J., Chan A. T. С., et al. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. J Clin Oncol 2017; 35 (5): 498–505.

24.

24. Yan M., Kumachev A., Siu L. L., Chan K. K. W. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. Eur J Cancer 2015; 51 (12): 1570–9.

Yan M., Kumachev A., Siu L. L., Chan K. K. W. Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: A Bayesian network meta-analysis. Eur J Cancer 2015; 51 (12): 1570–9.

25.

25. Langendijk J. A., Leemans C. R., Buter J., Berkhof J., Slotman B. J. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22 (22): 4604–12.

Langendijk J. A., Leemans C. R., Buter J., Berkhof J., Slotman B. J. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol 2004; 22 (22): 4604–12.

26.

26. Chen Y. P., Ismaila N., Chua M. L. K., Colevas A. D., Haddad R., Huang S. H., еt аl. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol 2021; 39 (7): 840–59. DOI: 10.1200/JCO.20.03237

Chen Y. P., Ismaila N., Chua M. L. K., Colevas A. D., Haddad R., Huang S. H., еt аl. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol 2021; 39 (7): 840–59. DOI: 10.1200/JCO.20.03237

27.

27. Lee J. Y., Sun J. M., Oh D. R., Lim S. H., Goo J., Lee S. H., et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol 2016; 118: 244–50.

Lee J. Y., Sun J. M., Oh D. R., Lim S. H., Goo J., Lee S. H., et al. Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02). Radiother Oncol 2016; 118: 244–50.

28.

28. Liang H., Xia W. X., Lv X., Sun R. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiC-TR-TRC-12001979). J Clin Oncol 2017; 35 (15 Suppl): 6006. DOI:10.1200/JCO.2017.35.15_suppl.6006

Liang H., Xia W. X., Lv X., Sun R. Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiC-TR-TRC-12001979). J Clin Oncol 2017; 35 (15 Suppl): 6006. DOI:10.1200/JCO.2017.35.15_suppl.6006

29.

29. Lee A. W., Tung S. Y., Ngan R. K., Chappell R., Chua D. T. T., Lu T. X., et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer 2011; 47: 656–66.

Lee A. W., Tung S. Y., Ngan R. K., Chappell R., Chua D. T. T., Lu T. X., et al. Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Combined analyses of NPC-9901 and NPC-9902 trials. Eur J Cancer 2011; 47: 656–66.

30.

30. Peng H., Chen L., Zhang Y., Li W. F., Mao Y. P., Zhang F., et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a prospective phase III clinical trial. Oncologist 2016; 21: 1369–76.

Peng H., Chen L., Zhang Y., Li W. F., Mao Y. P., Zhang F., et al. Prognostic value of the cumulative cisplatin dose during concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a prospective phase III clinical trial. Oncologist 2016; 21: 1369–76.

31.

31. Lee A. W., Ma B. B., Ng W. T., Chan A. T. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. J Clin Oncol 2015; 33 (29): 3356–64. DOI: 10.1200/JCO.2015.60.9347

Lee A. W., Ma B. B., Ng W. T., Chan A. T. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. J Clin Oncol 2015; 33 (29): 3356–64. DOI: 10.1200/JCO.2015.60.9347

32.

32. Yang Q., Cao S. M., Guo L., Hua Y. J., Huang P. Y., Zhang X. L., et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 2019; 119: 87–96. DOI: 10.1016/j.ejca.2019.07.007

Yang Q., Cao S. M., Guo L., Hua Y. J., Huang P. Y., Zhang X. L., et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer 2019; 119: 87–96. DOI: 10.1016/j.ejca.2019.07.007

33.

33. Zhang Y., Chen L., Hu G. Q., Zhang N., Zhu X. D., Yang K. Y., et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med 2019; 381 (12): 1124–35. DOI: 10.1056/NEJMoa1905287

Zhang Y., Chen L., Hu G. Q., Zhang N., Zhu X. D., Yang K. Y., et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med 2019; 381 (12): 1124–35. DOI: 10.1056/NEJMoa1905287

34.

34. Cao S. M., Yang Q., Guo L., Mai H. Q., Mo H.Y., Cao K. J., et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locore-gionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer 2017; 75: 14–23.

Cao S. M., Yang Q., Guo L., Mai H. Q., Mo H.Y., Cao K. J., et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locore-gionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer 2017; 75: 14–23.

35.

35. [Electronic resource]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed December 28, 2021).

[Electronic resource]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (accessed December 28, 2021).

36.

36. Zhang L., Huang Y., Hong S., Yang Y., Yu G., Jia J., et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016; 388 (10054): 1883–92. DOI: 10.1016/S0140-6736(16)31388-5

Zhang L., Huang Y., Hong S., Yang Y., Yu G., Jia J., et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet 2016; 388 (10054): 1883–92. DOI: 10.1016/S0140-6736(16)31388-5

37.

37. Casanova M., Özyar E., Patte C., Orbach D., Ferrari A., Veyrat-Follet C., et al. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol 2016; 77 (2): 289–98.

Casanova M., Özyar E., Patte C., Orbach D., Ferrari A., Veyrat-Follet C., et al. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents. Cancer Chemother Pharmacol 2016; 77 (2): 289–98.

38.

38. Жуков Н. В. Профилактика и лечение тошноты и рвоты у детей и подростков, получающих противоопухолевую терапию. Текущее состояние и потенциальные пути улучшения / Н. В. Жуков, Л. Л. Казакова, Г. А. Новичкова // Вопросы гематологии / онкологии и иммунопатологии в педиатрии. – 2020. – 19 (4): 205–23. DOI: 10.24287/1726-1708-2020-19-4-205-223

Жуков Н. В. Профилактика и лечение тошноты и рвоты у детей и подростков, получающих противоопухолевую терапию. Текущее состояние и потенциальные пути улучшения / Н. В. Жуков, Л. Л. Казакова, Г. А. Новичкова // Вопросы гематологии / онкологии и иммунопатологии в педиатрии. – 2020. – 19 (4): 205–23. DOI: 10.24287/1726-1708-2020-19-4-205-223

39.

39. Rodriguez-Galindo C., Krailo M. D., Krasin M. J., Huang L., McCarville M. B., Hicks J., et al. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. J Clin Oncol 2019; 37 (35): 3369–76. DOI: 10.1200/JCO.19.01276

Rodriguez-Galindo C., Krailo M. D., Krasin M. J., Huang L., McCarville M. B., Hicks J., et al. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. J Clin Oncol 2019; 37 (35): 3369–76. DOI: 10.1200/JCO.19.01276

40.

40. Ma B. B., Hui E. P., Wong S. C., Tung S. Y., Yuen K. K., King A., et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 2009; 20 (11): 1854–9.

Ma B. B., Hui E. P., Wong S. C., Tung S. Y., Yuen K. K., King A., et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol 2009; 20 (11): 1854–9.

41.

41. Dourthe M. E., Bolle S., Temam S., Jouin А., Claude L., Reguerre Y., et al. Childhood nasopharyngeal carcinoma: State-of-the-art, and questions for the future. J Pediatr Hematol Oncol 2018; 40: 85–92.

Dourthe M. E., Bolle S., Temam S., Jouin А., Claude L., Reguerre Y., et al. Childhood nasopharyngeal carcinoma: State-of-the-art, and questions for the future. J Pediatr Hematol Oncol 2018; 40: 85–92.

42.

42. Rodriguez-Galindo C., Wofford M., Castleberry R. P., Swanson G. P., London W. B., Fontanesi J., et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer 2005; 103: 850–7.

Rodriguez-Galindo C., Wofford M., Castleberry R. P., Swanson G. P., London W. B., Fontanesi J., et al. Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma. Cancer 2005; 103: 850–7.

43.

43. Sahai P., Mohanti B. K., Sharma A., Thakar A., Bhasker S., Kakkar A., et al. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy. Pediatr Blood Cancer 2017; 64 (2): 259–66.

Sahai P., Mohanti B. K., Sharma A., Thakar A., Bhasker S., Kakkar A., et al. Clinical outcome and morbidity in pediatric patients with nasopharyngeal cancer treated with chemoradiotherapy. Pediatr Blood Cancer 2017; 64 (2): 259–66.

44.

44. Mertens R., Granzen B., Lassay L., Bucsky P., Hundgen М., Stetter G., et al. Treatment of nasopharyngeal carcinoma in children and adolescents. Definitive results of a multicenter study (NPC-91-GPOH). Cancer 2005; 104: 1083–9.

Mertens R., Granzen B., Lassay L., Bucsky P., Hundgen М., Stetter G., et al. Treatment of nasopharyngeal carcinoma in children and adolescents. Definitive results of a multicenter study (NPC-91-GPOH). Cancer 2005; 104: 1083–9.

45.

45. Rusthoven C. G., Lanning R. M., Jones B. L., Amini А., Koshy M., Sher D. J., et al. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 2017; 124 (1): 139–46. DOI: 10.1016/j.radonc.2017.03.019

Rusthoven C. G., Lanning R. M., Jones B. L., Amini А., Koshy M., Sher D. J., et al. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 2017; 124 (1): 139–46. DOI: 10.1016/j.radonc.2017.03.019

46.

46. Hsu C., Lee S. H., Ejadi S., Even C., Cohen R. B., Le Tourneau C., et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol 2017; 35 (36): 4050–6. DOI: 10.1200/JCO.2017.73.3675

Hsu C., Lee S. H., Ejadi S., Even C., Cohen R. B., Le Tourneau C., et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol 2017; 35 (36): 4050–6. DOI: 10.1200/JCO.2017.73.3675

47.

47. Fang W., Yang Y., Ma Y., Hong S., Lin L., He X., et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19 (10): 1338–50. DOI: 10.1016/s1470-2045(18)30495-9

Fang W., Yang Y., Ma Y., Hong S., Lin L., He X., et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19 (10): 1338–50. DOI: 10.1016/s1470-2045(18)30495-9